Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: Insight into the interplay between hepatitis C virus infection and cellular immunity

Liver Transplantation

Volumn 14, Issue 9, 2008, Pages 1313-1322

  Mendler, Michel ^a   Kwok, Hansen ^a   Franco, Edson ^a   Baron, Pedro ^a   Weissman, Jill ^a   Ojogho, Okechukwu ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HYPOTHESIS; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT INDICATION;

ADENOSINE TRIPHOSPHATASES; ADULT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 51549116306     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21529     Document Type: Article

References (26)

1. Organ Procurement and Transplantation Network. Home page. Available at: http://www.optn.org. Accessed March 2007.
2. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
3. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13:975-983.
4. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-888.
5. Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc 2005;37:1700-1702.
6. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231.
7. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
8. Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, et al. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol 2007;123:235-243.
9. Sottong PR, Rosebrock JA, Britz JA, Kramer TR. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 2000;7:307-311.
10. US Department of Health and Human Services. K013169; Cylex Immune Cell Function Assay, April 02, 2002. Available at: http://www.fda.gov/cdrh/ pdf/k013169.pdf. Accessed April 2008.
11. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003;17:77-88.
12. Cadillo-Chavez R, de Echegaray S, Santiago-Delpin EA, Rodriguez-Trinidad AT, Camacho-Carrazo B, Alfaro T, et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 2006;38:918-920.
13. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-668.
14. Aberle JH, Formarm E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, et al. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006;36:24-31.
15. Della Bella S, Crosignani A, Riva A, Presicce P, Benetti A, Longhi R, et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology 2007;121:283-292.
16. Aberle JH, Perstinger G, Weseslindtner L, Sinzinger U, Gurguta C, Steindl-Munda P, et al. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. J Infect Dis 2007;195:1315-1319.
17. Pillai V, Lee WM, Thiele DL, Karandikar NJ. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. J Viral Hepat 2007;14:318-329.
18. Bonacini M, Govindarajan S, Kohla M, Lai MM, Lindsay KL. Intrahepatic lymphocyte phenotypes in hepatitis C virus infection: a comparison between cirrhotic and noncirrhotic livers. Minerva Gastroenterol Dietol 2007;53:1-7.
19. Anonymous. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
20. Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-293.
21. Gautam A, Fischer SA, Yango AF, Gohh RY, Morrissey PE, Monaco AP. Cell mediated immunity (CMI) and post transplant viral infections - role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol 2006;6:2023-2026.
22. Thai NL, Blisard D, Tom K, Basu A, Smetanka C, Tan H, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection [published correction in Transplantation 2007;83:236]. Transplantation 2006;82:1649-1652.
23. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
24. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41.
25. Belli LS, Alberti AB, Vangeli M, Airoldi A, Pinzello G. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003;9:201-202.
26. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84:829-835.